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Abstract
Background: The present study is aimed at identifying potential candidate genes as prognostic
markers in human oral tongue squamous cell carcinoma (SCC) by large scale gene expression
profiling.
Methods: The gene expression profile of patients (n=37) with oral tongue SCC were analyzed
using Affymetrix HG_U95Av2 high-density oligonucleotide arrays. Patients (n=20) from which
there were available tumor and matched normal mucosa were grouped into stage (early vs. late)
and nodal disease (node positive vs. node negative) subgroups and genes differentially expressed in
tumor vs. normal and between the subgroups were identified. Three genes, GLUT3, HSAL2, and
PACE4, were selected for their potential biological significance in a larger cohort of 49 patients via
quantitative real-time RT-PCR.
Results:  Hierarchical clustering analyses failed to show significant segregation of patients. In
patients (n=20) with available tumor and matched normal mucosa, 77 genes were found to be
differentially expressed (P< 0.05) in the tongue tumor samples compared to their matched normal
controls. Among the 45 over-expressed genes, MMP-1 encoding interstitial collagenase showed the
highest level of increase (average: 34.18 folds). Using the criterion of two-fold or greater as
overexpression, 30.6%, 24.5% and 26.5% of patients showed high levels of GLUT3, HSAL2 and
PACE4, respectively. Univariate analyses demonstrated that GLUT3 over-expression correlated
with depth of invasion (P<0.0001), tumor size (P=0.024), pathological stage (P=0.009) and
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recurrence (P=0.038).  HSAL2 was positively associated with depth of invasion (P=0.015) and
advanced T stage (P=0.047).   In survival studies, only GLUT3 showed a prognostic value with
disease-free (P=0.049), relapse-free (P=0.002) and overall survival (P=0.003). PACE4 mRNA
expression failed to show correlation with any of the relevant parameters. 
Conclusion: The characterization of genes identified to be significant predictors of prognosis by
oligonucleotide microarray and further validation by real-time RT-PCR offers a powerful strategy
for identification of novel targets for prognostication and treatment of oral tongue carcinoma.
Background
Cancer arising from the oral cavity accounts for approx-
imately 1.6% of all cancers diagnosed in the United
States with an incidence of 22,000 new cases per year
[1]. Despite the advances in multimodality treatment,
the overall prognosis for patients with oral squamous
cell carcinoma (SCC) has remained unchanged in the
past three decades. Furthermore, variability in the clin-
ical course of patients with oral SCC remains unex-
plained and conventional clinicopathological
parameters fail to answer all questions. Identification
of novel prognostic factors may allow a rational selec-
tion of the most appropriate therapeutic options for
individual patients. The cellular and molecular hetero-
geneity of oral SCC and the large number of genes
potentially involved in oral carcinogenesis and progres-
sion emphasize the importance of studying multiple
gene alterations on a global scale. Gene expression pro-
filing by high-throughput technologies have proven to
be valuable tools for prognostication of outcome and
progression in human malignancies including head
and neck cancer [2-10]. These technologies permit us to
classify individual cancers and enhance our under-
standing of molecular cancer pathogenesis.
There are several distinct subsites within the oral cavity
cancer including buccal mucosa, oral tongue, floor of
mouth, gingiva, retromolar trigone and hard palate.
Since they differ in their biological and clinical behav-
iors, the present study focused on one subsite – the oral
tongue. This study utilized high-density oligonucle-
otide array to generate a molecular portrait of oral
tongue SCC and to explore the correlations between
gene expression patterns and clinically relevant param-
eters. We performed hierarchical clustering analysis,
analyzed gene expression profiles by comparing pri-
mary tumor and their matched normal mucosa and
compared different patient groups based on lymph
node status and tumor stage to identify clinically signif-
icant genes. Data from the microarray analysis were
then validated by real-time RT-PCR. The present study
is the first to demonstrate the ability of gene expression
profiling to predict clinical outcome in one cancer sub-
site within the oral cavity.
Methods
Tumor Selection
Following guidelines established by the Institutional
Review Board at Memorial Sloan-Kettering Cancer Center
(MSKCC), fresh tissue samples were sequentially collected
after obtaining written informed consent from 49 patients
undergoing therapeutic surgical resection for SCC of the
oral tongue at the Head and Neck Service, MSKCC from
January 28, 1998 to January 2, 2002. Post-operative adju-
vant treatment was given to selected patients following
the institutional protocol. In each case, the portion of
tumor was resected near the advancing edge of the tumor
to avoid its necrotic center. After excision, the tissues were
immediately snap-frozen and stored in liquid nitrogen
until use. Histologically normal mucosae of the upper
aerodigestive tract, resected 5 cm away from the tumor
area, were obtained in all cases and used as controls.
Tumors were staged according to the AJCC/UICC TNM
classification 5th edition [11]. "Node-positive cases" in
this study refers to the presence of positive cervical nodes
based on a histological diagnosis after a neck dissection,
while the patients who experienced no metastasis for at
least 12 months post-operatively were scored as "node-
negative cases." The clinical and pathological characteris-
tics of all patients analyzed in the study are summarized
in Table 1.
Oligonucleotide microarray analysis
Tumor and normal tissues from 37 of the 49 patients were
used for the oligonucleotide microarray analysis. Twenty
(TN paired) of the 37 patients had primary tumor samples
and matched normal mucosa available for analysis. Total
RNA from snap-frozen tissue samples from the 37 patients
was extracted with TRIsol™ reagent (Gibco BRL) following
the manufacturer's protocol and re-purified by the RNAeasy
Mini-spin column (Qiagen). Five to 10 μg of total RNA was
reverse transcribed in the presence of an oligo dT-T7 primer.
The cDNA was used for in vitro transcription amplification
reaction in the presence of biotinylated nucleotides. Fifteen
μg of labeled cRNA was fragmented and then hybridized
against the Affymetrix HG_U95Av2 oligonucleotide arrays
(Affymetrix, Santa Clara, CA). The arrays were scanned using
a Hewlett Packard confocal laser scanner and analyzed using
MicroArray Suite 5.0 (Affymetrix).BMC Cancer 2009, 9:11 http://www.biomedcentral.com/1471-2407/9/11
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Table 1: Clinicopathological characteristics of the patients in the study and validation groups
Parameter Study (Array) Validation
All samples TN paired RT-PCR
NUMBER %
Total 37 20 49
Age (yrs)
Median (Range) 57 (36–97) 62 (35–97) 59 (35–97)
Gender
Male 22 (59.5) 12 (60) 26 (53)
Female 15 (40.5) 8 (40) 23 (47)
Therapy prior to surgery
None 22 (59.5) 12 (60.0) 34 (69.4)
Yes 15 (40.5) 8 (40.0) 15 (30.6)
Smoking history
Yes 19 (51.4) 11 (55.0) 30 (61.2)
No 18 (48.6) 9 (45.0) 19 (38.8)
Alcohol history
Yes 14 (37.9) 8 (40.0) 20 (40.8)
No 23 (62.1) 12 (60.0) 26 (59.2)
Unknown 0 0 3
Histological grading
Well-differentiated 6 (16.2) 3 (15) 9 (18)
Mod-differentiated 24 (64.9) 13 (65) 32 (65)
Poorly-differentiated 7 (18.9) 4 (20) 8 (16)
Unknown 0 0 0
Lymph node involvement (Pathologic)
Negative 26 (70.2) 13 (65) 25 (51)
Positive 11 (29.8) 7 (35) 24 (49)
Unknown 0 0 0
TNM Stage (Pathologic)BMC Cancer 2009, 9:11 http://www.biomedcentral.com/1471-2407/9/11
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The microarray data have been deposited in NCBIs Gene
Expression Omnibus (GEO) http://www.ncbi.nlm
.nih.gov/geo/ and can be accessed through GEO Series
accession number GSE13601.
RNA preparation and real-time RT-PCR
RT-PCR of GLUT3, HSAL2, and PACE4 was performed on
the larger cohort of 49 patients. Two μg of total RNA was
reverse transcribed with MultiScribe™ Reverse Tran-
scriptase (Applied Biosystems, Inc.). Gene specific primers
were designed using the Primer3 Program. Sequences of
PCR primer sets (in 5'-3' direction) were as follows:
GLUT3  forward: TAGAAAGCCTGTTCCCCTCA, GLUT3
backward: GTGGCGGGATTACTTCAAAA; HSAL2  for-
ward: CCCTCCTATTTCAGCCTCCT, HSAL2  backward:
TCTTCAGTACCGGCACCTTC;  PACE4  forward: CCTGT-
GTGACCCTCTGTCCT,  PACE4  backward: GGTTCATC-
CACGCACTTTTT. The sequence of PCR primer sets for
18S rRNA were previously described [12]. Quantification
of transcripts was performed by the ICycler Detection Sys-
tem (Bio-Rad Laboratories) using SYBR green detection.
The relative quantification of a target gene in comparison
to a reference (18S rRNA) was performed as described
[13]. Unless otherwise stated, each assay included dupli-
cate reactions for each sample and was repeated twice.
Statistical analysis
All correlation and outcome analysis was performed using
the JMP statistical software package version 4.0.0 (SAS
Institute, Inc.). Disease-free survival is defined as the time
from surgery to the day of the first recurrence or death.
Relapse-free survival was defined as time from surgery to
the day of the first recurrence. Overall survival was defined
as time from surgery to the day of death or last follow-up.
Results and discussion
Gene expression patterns in oral tongue SCC
We analyzed gene expression profiles in 20 patients with
oral tongue SCC by comparison between primary tumor
samples and their matched morphologically normal
mucosa. Among 12,625 probe sets in the Affymetrix
array, 77 probe sets had statistically significant difference
(P < 0.05) between all tumors and their matched normal
tissues. There were 60 probe sets representing 45 genes
and 11 ESTs that were increased and 17 probe sets repre-
senting 9 genes and 8 ESTs that were decreased in tumors
compared to normal controls. Table 2 lists the genes that
were up-regulated or down-regulated along with the fold
changes in gene expression in tumor compared to their
normal counterparts. These include genes known to be
relevant in oncogenesis such as cell proliferation, apop-
tosis, development, angiogenesis, invasion and metasta-
sis as well as genes that have not been implicated in oral
tongue carcinogenesis. Among the 45 over-expressed
genes, MMP-1 encoding interstitial collagenase showed
the highest level of increase (average: 34.18 fold). MMP-
7  and  MMP-12  were also found to be overexpressed.
Matrix metalloproteinases (MMPs), a family of 23
human zinc-dependent extracellular endopeptidases
involved in the degradation of extracellular matrix and
basement membrane during tumor cell invasion, have
been implicated in a number of different human tumors
including head and neck SCC [14,15]. Not surprisingly,
enhanced MMP-1 expression has been found to be asso-
ciated with malignant progression as well as poor out-
come in head and neck SCC [15-17]. Likewise, MMP-7
and  MMP-12  have both been implicated in tumor
aggressiveness in oral SCC [18]. Genes that have been
shown to be involved in epithelial development and dif-
ferentiation such as the cytokeratins KRT16 and KRT17
were found to be overexpessed. In their study investigat-
ing RNA from head and neck SCC and normal tissues,
Villaret et al. (2000) found KRT6 and KRT16 to be the
genes most commonly expressed [19]. Similarly, KRT16
has also been found to be highly expressed in squamous
cell carcinoma of the skin [20]. In addition, those that
play a role in angiogenesis, such as hypoxia-inducible
factor (HIF-1 ) and platelet-derived endothelial cell
growth factor (ECGF1) were also overexpressed. Several
transcripts were found to be significantly under-
expressed or absent in tumor compared with matched
normal tissues including those that encode for cell sur-
face (CO-029), nuclear (ZAKI-4) and extracellular pro-
teins (hSBP).
I 8 (21.6) 4 (20) 11 (22)
II 12 (32.4) 6 (30) 12 (25)
III 3 (8.1) 3 (15) 7 (14)
IV 14 (37.9) 7 (35) 19 (39)
Unknown 0 0 0
Table 1: Clinicopathological characteristics of the patients in the study and validation groups (Continued)BMC Cancer 2009, 9:11 http://www.biomedcentral.com/1471-2407/9/11
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Table 2: Genes differentially expressed between oral tongue tumor and case-matched histologically normal mucosae (TN paired, n = 
20)
Accession Sequence identity (GenBank/EMBL) Average log fold change
Nuclear proteins (transcription factors, DNA processing enzymes)
AJ001381 Mutated allele of a myosin class I, myh-1c 5.24
D28364 Annexin II 4.61
M92383 Thymosin beta-10 3.75
U22431 Hypoxia-inducible factor 1 alpha (HIF-1 alpha) 3.47
M86400 Phospholipase A2 3.27
L19779 Histone H2A.2 2.99
U10860 Guanosine 5-monophosphate synthase 2.71
U12472, U21689 Glutathione S-transferase (GST phi) 2.70
J04173 Phosphoglycerate mutase (PGAM-B) 2.69
AL009179 Histone H2B 2.58
D13748 Eukaryotic initiation factor 4AI 2.57
S79639 Exostosin 1 (EXT1) 2.39
AL049650 snRNP (small nuclear ribonucleoprotein particle) protein B) 2.35
Ras-Like Protein Tc4 2.27
D26599 Proteasome subunit HsC7-I 2.04
X82554 SPHAR gene for cyclin-related protein -1.89
U40490 Human nicotinamide nucleotide transhydrogenase -3.53
D83407 ZAKI-4 in human skin fibroblast -5.31
Cytokines, growth factors and receptors
NM001953, M63193 Platelet-derived endothelial cell growth factor (ECGF1) 15.89
M77349 Transforming growth factor-beta induced gene product (BIGH3) 6.17
U73377 p66shc (SHC) 2.37
M35252 Tumor associated antigen CO-029 -9.42
Signaling molecules
AF054183 GTP binding protein 2.00
U78525 Eukaryotic translation initiation factor (eIF3) 1.89BMC Cancer 2009, 9:11 http://www.biomedcentral.com/1471-2407/9/11
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Metabolic enzymes, transporters, ion channels
AF042498 Rod photoreceptor CNG-channel beta subunit (RCNC2) 6.73
M94856 Fatty acid binding protein homologue (PA-FABP) 5.24
M91670 Ubiquitin carrier protein (E2-EPF) 3.52
J03626 UMP synthase 2.54
D50840 Ceramide glucosyltransferase 2.54
U89606 Pyridoxal kinase 2.41
Accession Sequence identity (GenBank/EMBL) Average log fold change
X52851 Cyclophilin 2.22
X97074 Clathrin-associated protein 2.07
S81003 L-UBC = ubiquitin conjugating enzyme 2.04
U09510 Glycyl-tRNA synthetase 1.96
D25547 PIMT isozyme I 1.87
AF052941 DAP-kinase related protein 1 -2.12
D16294 Mitochondrial 3-oxoacyl-CoA thiolase -3.59
Extracellular proteins
M13509 Skin collagenase (MMP1) 34.18
X07820 Stromelysin-2 (MMP7) 15.89
L10343 Elafin 9.95
L23808 Macrophage metalloelastase (MME, MMP12) 7.67
U29091 Human selenium-binding protein (hSBP) -5.41
Others
AB018342 KIAA0799 4.44
D21261 KIAA0120 2.59
AB014515 KIAA0615 2.42
AB007889 KIAA0429 2.09
AA586894 EST 14.57
AA010777 EST 14.12
L05424 EST 5.76
Table 2: Genes differentially expressed between oral tongue tumor and case-matched histologically normal mucosae (TN paired, n = 
20) (Continued)BMC Cancer 2009, 9:11 http://www.biomedcentral.com/1471-2407/9/11
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AI885852 EST 4.03
Z98946 EST 3.42
AC002073 EST 3.17
AF053356 EST 1.73
AB028994 KIAA1071 -6.08
D42047 KIAA0089 -4.68
AB007972 KIAA0503 -3.96
AF007153 EST -5.35
AI674208 EST -3.57
AL080059 EST -3.12
AL049381 EST -2.93
AW021542 EST -2.60
Table 2: Genes differentially expressed between oral tongue tumor and case-matched histologically normal mucosae (TN paired, n = 
20) (Continued)
Hierarchical clustering analysis
Four separate clustering analyses were performed: (1) All
tumor and normal samples (TN, n = 37), (2) the tumor
and their matched normal samples (TN paired, n = 20);
(3) the tumor samples by themselves (T, n = 31); and (4)
the normal samples by themselves (N, n = 26). The data
were clustered using the standard hierarchical method
with ward linkage and using the Pearson correlation to
determine the distance function. The distance between
samples was dist = (1-p)/2 where p is the correlation coef-
ficient. Before clustering, the data was filtered to remove
genes that were scored Absent (A) by the MAS5.0 software
in 75% or more of the samples as they are likely to be
measuring noise in the system. To assess the robustness of
the clustering results, a resampling method was used to
create 1000 replica datasets by adding Guassian noise to
each point. These 1000 data sets were individually clus-
tered and then a consensus tree was built from them. The
number at each node in the tree indicates how often that
subtree appears in the 1000 replica trees. The higher the
number, the more robust is the subtree. The samples from
the TN cluster set clearly segregated the tumor from the
normal samples (Figure 1A). Similarly, TN paired set sep-
arated the tumor samples from their matched normal
counterparts (Figure 1B). The two clusters exhibit nearly
identical patterns of gene expression changes. As shown
on Table 2, the genes that were overexpressed included
those involved in tumor invasion, epithelial development
and angiogenesis. In contrast, however, clustering analysis
failed to show significant segregation of patients based on
expression profiling in both the T and N cluster sets pos-
Hierarchical clustering of the gene expression data for the  TN cluster set, N = 37 Figure 1
Hierarchical clustering of the gene expression data 
for the TN cluster set, N = 37. A; and the TN paired clus-
ter set, N = 20. B. Approximately 12, 625 genes were clus-
tered using the method described in the text. The genes 
shown represent the top 80 genes that were up-regulated 
(red) and down-regulated (green) in the sample sets. The 
normal tissue (N) and tumor tissue (T) are followed by their 
corresponding case numbers.
A          BBMC Cancer 2009, 9:11 http://www.biomedcentral.com/1471-2407/9/11
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sibly due to the heterogeneous nature of the samples as
well as the relatively small number of samples in this
study (Figure 2).
Assessment of correlation with lymph node status, stage 
and outcome
We grouped patients with pathologic stages I and II dis-
ease into an early-stage disease and grouped patients with
pathologic stages III and IV disease into a late-stage dis-
ease category. Through statistical regression analysis, we
identified genes whose expression differed in tumor ver-
sus normal mucosa and those whose expression was most
different between the staging subgroups (Table 3A). The
same analysis was performed to compare patients without
cervical nodal metastasis (N0) to those with nodal disease
(N1–N3) (Table 3B). We analyzed data from patients (n =
20) for which tumor and matched normal mucosae were
available and not the larger subgroup of patients (n = 37)
in order to obtain a more meaningful comparison of gene
expression changes between tumor and normal mucosa.
We selected three genes, GLUT3, HSAL2 and PACE4 for
further analysis and validation in a larger cohort of 49
patients. We selected genes with known important roles in
cellular functions and carcinogenesis and for which anti-
bodies were available. We employed a two-step quantita-
tive RT-PCR to validate expression changes identified by
gene array analysis for the three selected genes in all 49
cases. We defined the cut-off value for over-expression as
two-fold or greater relative to matched normal controls.
Using these criteria, 30.6%, 24.5% and 26.5% of patients
expressed high levels of GLUT3, HSAL2 and  PACE4,
respectively. We assessed the prognostic significance of
expression of the selected genes and various clinicopatho-
logical parameters. Univariate analyses demonstrated that
GLUT3 over-expression correlated with depth of invasion
(P < 0.0001), tumor size (P = 0.024), pathological stage (P
= 0.009) and recurrence (P = 0.038). HSAL2 was posi-
tively associated with depth of invasion (P = 0.015) and
advanced T stage (P = 0.047). PACE4 expression failed to
show correlation with clinicopathological parameters.
Table 4 depicts the univariate analysis of GLUT3, HSAL2
and  PACE4  expression and various clinicopathologic
parameters. In survival studies, only GLUT3  showed a
prognostic value with disease-free survival (P = 0.049),
relapse-free survival (P = 0.002) and overall survival (P =
0.003) (Figure 3). Multivariate analysis with Cox's pro-
portional hazards revealed that all parameters remained
independent prognosticators in this group of patients.
Hierarchical clustering of tumor (T), N = 31 Figure 2
Hierarchical clustering of tumor (T), N = 31. A; and normal (N), N = 26. B cluster sets based on the complete panel of 
12,000 genes. Horizontal distance represents the correlation of the samples to one another. The numbers at each node repre-
sent frequency of the shown pattern using 1,000 iteration bootstrap resampling.
   aaaa 
A           BBMC Cancer 2009, 9:11 http://www.biomedcentral.com/1471-2407/9/11
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Malignant cells show an increased glucose uptake in vitro
and in vivo [21,22]. This process is thought to be medi-
ated by glucose transporters (GLUTs), the expression and
activity of which is regulated by oncogenes, growth factors
and cytokines [23,24]. Studies of GLUT genes in human
cancers have shown over-expression of GLUT1 and
GLUT3 in cancers of various sites including the head and
neck [25-28]. Recent studies in laryngeal carcinoma dem-
onstrated an association between GLUT3 protein levels
and poorer outcome [29]. HSAL2 is a member of a gene
family that encodes a group of putative transcription fac-
tors. Evidence from various studies suggests that the HSAL
gene family is necessary for normal embryonic develop-
ment and genetic alterations can lead to human congeni-
tal defects and cancer [30,31]. HSAL2 is thought to have a
role as a tumor suppressor gene in ovarian cancer [32].
The present study suggests the potential role of GLUT3
and HSAL2 in oral tongue SCC. Proprotein convertases
(PC) are a family of serine endoproteases that play impor-
tant roles in regulating cell function by converting propro-
teins to biologically active molecules such as
neuropeptides and polypeptide hormones, protein tyro-
sine phosphatases, growth factors and their receptors, and
enzymes including MMPs. Numerous members of the PC
family have been associated with invasion and prolifera-
tion in various cancers including head and neck, breast
and lung cancers [33-35]. PCs are thought to activate cer-
tain substrates that may play a significant role in carcino-
genesis. Among these substrates are MMPs which are
known to be involved in the degradation of extracellular
matrix, a key process in the initiation of tumor microinva-
sion into the connective tissue. PACE4, a member of the
PC family, activates membrane type MMPs (MT-MMPs).
Bassi et al. demonstrated that PACE4 expression results in
enhanced susceptibility to carcinogenesis in vivo [35]. In
the present study, PACE4 failed to show clinical signifi-
cance when validated by real-time RT-PCR likely due to
the small sample size and heterogeneous nature of the
specimens.
There is growing literature on the use of microarray tech-
nology to examine genomewide genetic expression
changes associated with head and neck SCC development
and to identify biomarkers as it relates to response to ther-
apy and clinical outcome [5-10]. However, there is dis-
cordance among the studies. Furthermore, the biomarkers
Kaplan-Meier plot showing over-all survival Figure 3
Kaplan-Meier plot showing over-all survival. A; relapse-free survival. B; and disease-free survival. C in patients demon-
strating GLUT3 over-expression.
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Table 3: Differentially expressed genes associated with cervical lymph node and pathologic stage status
p-value Number present t-score Accession: Definition/Description or EST name
0.001% 30 5.324 M20681: Human glucose transporter-like protein-III (Glu3)
0.006% 10 4.525 X71125: H. sapiens mRNA for glutamine cyclotransferase
0.011% 10 3.943 X51757: HAP70B Human heat-shock protein HSP70B gene
0.014% 16 4.519 AB028957: H. sapiens mRNA for KIAA1034 protein
0.025% 26 4.261 Protein Phosphatase inhibitor homolog
0.021% 30 4.568 Y12065: H. Sapiens mRNA for nucleolar protein hNop56
0.031% 29 4.272 AB015633: Homo sapiens mRNA for type II membrane protein
0.031% 8 4.517 D78579: Homo sapiens mRNA for neuron derived orphan receptor
0.031% 17 3.764 W25985: 17e6
0.044% 31 3.792 AF007140: Homo sapiens clone 23711 unknown mRNA
0.061% 31 3.659 X86163: H. sapiens mRNA for B2-bradykinin receptor
0.064% 31 3.706 A1935420: wo84c08
0.076% 8 3.188 AB020654: Homo sapiens mRNA for KIAA0847 protein
0.076% 7 3.246 L23959: HUMDP1A Homo sapiens E2F-related transcription factor (DP-1) mRNA
0.090% 31 2.808 AL09674: Homo sapiens mRNA: cDNA DKFZp58600223
0.090% 21 3.544 Z11697: Homo sapiens mRNA for HB 15
0.090% 22 3.813 X98834: H. sapiens mRNA for zinc finger protein, Hsal2
0.106% 16 3.720 M81750: H. sapiens myeloid cell nuclear differentiation antigen mRNA
0.106% 25 3.943 S68134: CREM = cyclic AMP-responsive element modulator beta isoform
0.125% 31 3.302 X98296: H. sapiens mRNA for ubiquitin hydrolase
0.147% 26 3.051 U49392: Human allograft inflammatory factor-1 (AIF-1) mRNA
0.193% 7 3.269 AL109669: Homo sapiens mRNA full length insert cDNA clone EUROIMAGE
0.195% 5 2.861 M31166: HUMTSG14A Human tumor necrosis factor-inducible (TSG-14) mRNA
A
p-value Number present t-score Accession: Definition/Description or EST name
0.016% 31 4.286 AA402538: Soares ovary tumor NbHOT Homo sapiens cDNA
0.035% 22 3.690 X98834: H. sapiens mRNA for zinc finger protein, Hsal2
0.035% 26 3.501 U49392: Human allograft inflammatory factory-1 (ALF-1) mRNABMC Cancer 2009, 9:11 http://www.biomedcentral.com/1471-2407/9/11
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often lack predictive power. Two important limitations of
the studies to date are the heterogeneity in subsites ana-
lyzed and the small number of study samples. Our study
as well as that of others addressed the former by focusing
only on oral tongue SCC [36-38]. Carinci et al. analyzed
gene expression in 9 specimens with dysplasia, 8 with oral
tongue SCC with no metastasis, and 11 with metastatic
oral tongue SCC. Several genes were identified as poten-
tial markers of oral tongue progression and metastasis
[36]. Shimada and colleagues identified 16 genes that
were upregulated in 4 oral tongue SCC specimens. One
gene, RabIA, a member of the Ras oncogene, was chosen
and validated at the RNA and protein levels [37]. In a
study by Zhou et al., 25 primary oral tongue SCC were
0.043% 5 3.782 X62055: H. sapiens PTP1C mRNA for protein-tyrosine phosphate
p-value Number present t-score Accession: Definition/Description or EST name
0.062% 11 3.514 AB023135: Homo sapiens mRNA for activation-inducible lymphocyte
immunomediatory molecule AILIM
0.062% 31 3.698 A1828166: wk32h09
0.073% 31 3.761 U85773: Human phosphomannomutase (PMM2) mRNA
0.085% 6 3.501 S67970: ZNF75 = KRAB zinc finger [human, lung fibroblast, mRNA
0.104% 16 3.709 M81750: H. sapiens myeloid cell nuclear differentiation antigen mRNA
0.104% 31 3.824 AA121509:zk88c10.s1
p-value Number present t-score Accession: Definition/Description or EST name
0.104% 21 3.023 Z11697: Homo sapiens mRNA for HB15
0.104% 31 3.952 D67031: Homo sapiens ADDL mRNA for adducin-like protein
0.123% 29 3.565 J02923: Human 65-kilodalton phosphoprotein (p65) mRNA
0.123% 21 3.271 L10717: Homo sapiens T cell-specified tyrosine kinase mRNA
0.145% 26 2.955 AL031228:dJ1033B10. 10/Membrane protein with histidine rich charge clusters
0.145% 24 3.512 AB011102: Homo sapiens mRNA for KIAA0530 protein
0.170% 25 2.843 M80482: Human subtilisin-like protein (PACE4) mRNA
0.199% 19 3.215 AF072099: Homo sapiens immunoglobulin-like transcript 3protein variant 1 gene
0.199% 28 3.319 J03037: Human carbonic anhydrase II mRNA
0.199% 31 2.979 D21261: Human mRNA for KIAA0120 gene
0.199% 31 3.542 L06797: HUMGPCR Human (clone L5) orphan G protein-coupled receptor mRNA
B
The 20 patients were grouped into early-stage (Stage I and II disease) category and late-stage (Stage III and IV disease) category. A; Similarly, patients 
without cervical nodal metastasis (N0) were compared to those with nodal disease (N1–N3). B; Genes whose expression in tumor was different in 
normal mucosa and which were most different between the clinical stage and nodal disease subgroups were identified by statistical regression 
analysis (t test). The genes identified within the two subgroups are listed. Note that HSAL2 were identified in both subgroups. Only genes that were 
present in at least 5 samples were included.
Table 3: Differentially expressed genes associated with cervical lymph node and pathologic stage status (Continued)BMC Cancer 2009, 9:11 http://www.biomedcentral.com/1471-2407/9/11
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classified based on lymph node status and the presence of
extracapsular spread. Among the genes that were shown to
be associated with metastasis included MMP-9  [38].
Our findings show overexpression of numerous genes
that have been previously shown in other DNA microar-
ray studies to have a potential role in the development of
head and neck carcinogenesis; these include MMP-1 and
KRT16. Furthermore, we have identified and validated
GLUT3 and HSAL2 to be potential prognosticator of head
and neck SCC. Although the present study, like the others,
is based on a relatively small number of patients and the
findings do not allow us to draw definitive conclusion
regarding their biological importance, it is the first to use
large scale transcriptional profiling for predicting survival
outcome in oral tongue SCC.
Conclusion
The use of high-density oligonucleotide probe arrays to
identify gene expression differences between oral tongue
SCC and normal tissues provide powerful means to
decode the molecular events involved in the genesis and
progression of oral SCC. Although these initial findings
will need to be validated in relationship to clinical param-
eters and outcome in larger patient cohorts, the character-
ization of genes identified to be significant predictors by
oligonucleotide microarray analysis may provide novel
targets for the prognostication and treatment of oral cavity
cancer. Finally, a large multi-institutional study including
specimens of uniform characteristics using independent
techniques to verify gene expression at the RNA, DNA and
protein levels will be vital in reaching our ultimate of goal
of improving the care of head and neck cancer patients.
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